Otsuka Holdings Co., Ltd.

LUND, SE / ACCESS Newswire / October 27, 2026 / Cantargia AB (publ) (NASDAQ Stockholm:CANTA) today announced that representatives from the company's executive management will hold a company presentation and participate in investor meetings at the Stifel 2026 Healthcare Conference in New York, November 10, 2026. Location: Lotte NY Palace, New York Format: Company Presentation by Hilde Steineger, CEO Date and Time: Tuesday November 10 at 9:20 - 9:50 AM ET (3:20 - 3:50 PM CET) Webcast: Link to webcast In addition, Cantargia will be presenting at the Biostock Life Science Summit November 5 in Lund, Sweden. For more information, please follow the link to the event. Live webcasts and replays, when available, can be found under the Newsroom section on Cantargia's homepage at . The archived webcast will be available for replay for at least 30 days. For further information, please contact Hilde Steineger, CEO Telephone: +46 (0)46-275 62 60 E-mail: info@cantargia.com About Cantargia Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer and non-small cell lung cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases. In September 2025, the acquisition of CAN10 by Otsuka Pharmaceutical was completed. Cantargia is listed on Nasdaq Stockholm (ticker:CANTA). More information about Cantargia is available at . Attachments Cantargia to Present at the Stifel 2026 Healthcare Conference SOURCE: Cantargia View the original press release on ACCESS Newswire

LUND, SE / ACCESS Newswire / October 26, 2026 / Cantargia AB (publ)(STO:CANTA), a clinical-stage biotechnology company focused on antibody-based therapeutics targeting IL1RAP, today announced the appointment of Monic Stuart, MD, PhD, MBA as Chief Medical Officer, effective immediately. Dr. Stuart will lead the clinical development of nadunolimab across hematological cancers and solid tumors. "I am extremely pleased that Dr. Stuart has decided to join Cantargia. Her background as a hematologist-oncologist and her experience from Genentech and Revolution Medicines in developing targeted treatments for solid tumors are a strong match for nadunolimab, which we are developing in both hematological cancers and solid tumors," said Hilde Steineger, CEO of Cantargia. "Her expertise will be especially valuable as we advance our MDS/AML program and, not least, as we take the next steps in pancreatic cancer (PDAC), where patients urgently need better treatment options." Dr. Stuart brings more than 20 years of oncology drug development experience, combining senior leadership roles at biotechnology and pharmaceutical companies with strategic clinical development advisory work for approximately 35 companies worldwide. Her expertise spans hematologic malignancies and solid tumors, encompassing early- and late-stage clinical development, clinical trial design, and regulatory strategy. She has served as Interim Chief Medical Officer or Head of Clinical Development for multiple biotechnology companies, including Acerta Pharma, where she oversaw the initial New Drug Application (NDA) submission for Calquence (acalabrutinib) and the planning of additional Phase 3 studies, and Revolution Medicines, where she contributed to clinical development strategies for early-stage oncology programs. Previously, Dr. Stuart held senior leadership positions at Genentech, where she contributed to multiple hematology programs and served as Global Development Lead for Perjeta (pertuzumab) during Phase 3 development, and at Geron Corporation, where she established clinical development programs in myelodysplastic syndromes (MDS) and myelofibrosis. She began her career at Stanford University as a bone marrow transplant physician and clinical investigator, leading clinical trials in acute myeloid leukemia (AML) and MDS. Dr. Stuart earned her medical degree from the University of North Carolina at Chapel Hill and a Masters of Public Health degree from Johns Hopkins University. She completed her residency and fellowships in hematology and bone marrow transplantation at Stanford University. "Throughout my career, from hematology to targeted therapies in solid tumors, I have been drawn to programs that can change the treatment landscape for patients with difficult-to-treat cancers. Nadunolimab is such a program, and I am very pleased to join Cantargia as we advance our work in MDS/AML and pancreatic cancer."" said Dr. Stuart. For further information, please contact Hilde Steineger, CEO Telephone: +46 (0)46-275 62 60 E-mail: info@cantargia.com About Cantargia Cantargia AB (publ,), reg. no. 556791-6019, is a biotechnology company developing antibody-based therapies for life-threatening diseases by targeting IL1RAP, a protein implicated in multiple cancer indications and inflammatory diseases. The Company's lead program, nadunolimab, is in clinical development in multiple cancer indications including pancreatic ductal adenocarcinoma, myelodysplastic syndrome, acute myeloid leukemia, and non-small cell lung cancer. In September 2025, Otsuka Pharmaceutical completed its acquisition of the Company's second program, CAN10, which blocks IL1RAP signaling through a distinct mechanism and was developed for serious autoimmune and inflammatory diseases. CAN10 was discovered through CANxx, Cantargia's antibody discovery engine, which is now advancing next-generation IL1RAP-directed candidates, including bispecific antibodies and antibody-drug conjugates, in preclinical development. Cantargia is listed on Nasdaq Stockholm (ticker:CANTA). More information about Cantargia is available at . Attachments Cantargia appoints Dr. Monic Stuart as Chief Medical Officer SOURCE: Cantargia View the original press release on ACCESS Newswire

The PMCPA has ruled that Otsuka Europe’s involvement with a sponsored symposium webpage breached 11 clauses of the U.K. marketing code. While the PMCPA found fault with many aspects of the webpage, the watchdog opted against hitting Otsuka with its toughest punishment. A complainant calling themselves an ex-employee triggered the case after becoming concerned about online content for an Otsuka-sponsored symposium at a 2025 healthcare congress. The complainant alleged that the webpage included a misleading sponsorship statement and promoted Otsuka’s Lupkynis (voclosporin), a lupus nephritis drug, off-label. The PMCPA broadly agreed with the complainant. “The webpage, which was accessible to the public, promoted voclosporin outside the terms of its marketing authorization and omitted important obligatory information such as the prescribing information and adverse event reporting statement,” the PMCPA said. That finding led the watchdog to conclude that Otsuka had failed to maintain high standards and breached Clause 5.1. Otsuka accepted that its actions amounted to a breach of the clause. However, the PMCPA ruled no breach of Clause 2, which it reserves for failings that bring discredit upon, or reduce confidence in, the pharmaceutical industry. The PMCPA spared Otsuka from that punishment after concluding that the company “appeared to have been let down” by event organizers. Otsuka was ultimately responsible for the content, but its culpability was limited by the omission of the contentious text from the drafts that it checked before publication. Clause 5.1 was one of multiple parts of the code that Otsuka accepted it had breached in its response to the complaint. The PMCPA ruled Otsuka had breached clauses related to advertising a prescription-only medicine to the public, making a misleading claim and failing to certify promotional materials, among other failings. The U.K. watchdog published its findings two years after sharing details of another complaint filed by a former Otsuka employee. In that case, the PMCPA found the company’s Jinarc training website breached Clause 2.